Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

1.23 0.97 1.01 0.00
P/S ratio
5.13 3.94 4.92 4.26
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(4.11) (8.44) (3.98) (3.49)
P/B ratio
2.17 2.73 2.93 3.56
Price to Tangible BV
4.98 11.26 6.98 13.68
EV/Sales
5.68 4.89 5.88 6.35
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(2.34) (1.49) (1.62) (1.74)
EV/FCF
(2.31) (1.48) (1.61) (1.73)
Quick Ratio
1.19 1.36 1.43 1.58
Current Ratio
1.24 1.47 1.56 1.77
Net Debt/EBITDA
3.57 3.00 3.68 2.16
Debt/Assets
7.16% 14.34% 13.96% 19.48%
Debt/Equity
0.42 0.61 0.47 0.61
Asset Turnover
0.07 0.12 0.15 0.16
Operating CF/Net income
1.30 0.52 1.51 3.01
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
(19.07) (20.40) (16.54) (13.92)
Research and Development Expense of Revenue
235.52% 242.97% 175.00% 149.87%
Selling, General and Administrative Expense of Revenue
215.46% 185.20% 187.68% 146.46%
Intangible Assets out of Total Assets
0.10 0.18 0.17 0.24
Share Based Compensation of Revenue
29.29% 21.84% 19.37% 18.05%
Graham Net Nets
0.17 0.06 0.08 0.02
Graham Number
4.75 4.14 4.65 0.00
Earnings Yield
81.10% 102.82% 98.82% (73.57%)
Free Cash Flow Yield
(47.81%) (83.84%) (74.41%) (86.26%)
Revenue per Share
0.10 0.11 0.09 0.09
Operating CF per Share
(0.40) (0.17) (0.42) (0.40)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.40) (0.17) (0.42) (0.40)
Cash per Share
1.65 1.47 1.22 0.68
Shareholders Equity per Share
0.76 0.52 0.58 0.39
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.76 0.52 0.58 0.39
Free Cash Flow
(46.34) (19.72) (57.89) (62.09)
Working Capital
88.66 66.32 73.70 58.28
Net Current Asset Value
32.21 9.38 18.64 3.44
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
224.65 70.38 42.47 66.95
Average Payables
23.39 19.19 26.20 25.40
Average Inventory
24.84 3.69 4.17 5.09
Average Assets
510.76 353.44 318.54 315.32
Average Common Equity
(0.10) (35.49) (52.42) 90.33

Fold the line items

Columns are period end dates